3 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
Follow Refractory WHO Grade 2 Glioma: new trials by email Literature Review of Refractory WHO Grade 2 Glioma trials Research Report on Refractory WHO Grade 2 Glioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-10-16 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-07-01 |
Ependymoma (3) · Glioma (3) · Hepatoblastoma (3) · Histiocytosis, Langerhans-Cell (3) · Lymphoma, Non-Hodgkin (3) · Medulloblastoma (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Osteosarcoma (3) · Rhabdoid Tumor (3) · Rhabdomyosarcoma (3) · Sarcoma (3) · Sarcoma, Ewing (3) · Wilms Tumor (3) · Lymphoma (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Female Urogenital Diseases (3) · Female Urogenital Diseases and Pregnancy Complications (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Histiocytosis (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Kidney Diseases (3) · Kidney Neoplasms (3) · Lung Diseases (3) · Lung Diseases, Interstitial (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Male Urogenital Diseases (3)
Magnetic Resonance Spectroscopy (1) · Nuclear Medicine Department, Hospital (1) · Phantoms, Imaging (1) · X-Rays (1) · ivosidenib (1) · selpercatinib (1) · tipifarnib (1)
National Cancer Institute (NCI) (3)
Puerto Rico (3) · United States (3) · Australia (2)
Andrea T Franson (1) · Christine A Pratilas (1) · Elizabeth D Alva (1)
U10CA180886 (3)